ASCO never fails to make its mark as the oncology conference to watch, no matter which way the data are. What pipelines are going to swell — or fade — as the readouts surface? Is a reshaping of the cancer landscape in the cards this year or will slow and steady win the race? Join Endpoints News’ ASCO experts panel to recap the news you don’t want to miss — and more.
11:00 - 11:25 amFireside
11:30 - 12:25 pmExperts Panel
01:30 - 02:25 pmSummoning Success by Accelerating Development in Novel and Advanced Oncology Therapies
02:30 - 03:25 pmEmerging targeted therapies for gliomas with IDH mutations
11:00 - 11:25 am
An in-depth discussion featuring Endpoints’ Senior Science Correspondent Ryan Cross and an industry leader — more to come.
1:30 - 2:25 pm
How to accelerate development in novel & advanced oncology therapies — from the starting line
What ways are we innovating CAR-T, ADCs, Immunotherapies, and mRNAs as they wind their way through the pipeline and beyond? How can we set up trials with the end game in mind? What are the key considerations to accelerate oncology clinical development timelines to support a global program strategy? Join our panel to dissect the shift in early phase oncology design with a particular focus on Bayesian Data.
2:30 - 3:25 pm
Emerging targeted therapies for gliomas with IDH mutations
The emergence of IDH gene mutations in gliomas as a therapeutic target has prompted a wave of action around treating these invasive brain tumors found primarily in adults. Recent research data shows that these IDH mutations play a causal role in tumor genesis and thus change the treatment landscape. What does the landscape look like now? What new approaches are in the pipeline?
Join us as we outline:
- Clinical features and diagnosis of the IDH-mutant gliomas
- Current treatment modalities and unmet medical needs
- Emerging new targeted therapies